DeSci project Hetu releases v3.0, a tri-layered Ethereum protocol (HETU, FLOW, CREDIT) that converts verified intelligence into liquid capital, introduces agent settlement and Proof of Causal Work, and seeks to define sovereign AI money.
The market is shifting away from traditional crypto valuation metrics and toward assets backed by strong narratives, tighter float, institutional support, and large-scale growth expectations, with TON and BIO as key examples.
JoinCare has announced a new strategic seed round with participation from Titans Ventures, DI Foundation, and Candaq Ventures. The company said the proceeds will be used to upgrade its core infrastructure and the CareAgents AI-assisted research system, while also expanding its global pipeline of early-stage biopharmaceutical projects and its network of scientific and medical advisors. The funding will also support development of JoinCare’s ecosystem applications and Launchpad. JoinCare is building an open DeSci incubation network focused on early-stage biopharmaceutical innovation. By linking research teams, scientific and medical experts, ecosystem builders, and community participants, the platform aims to support projects across discovery, scientific evaluation, and collaborative incubation. Looking ahead, JoinCare plans to extend this framework to research institutions and innovation teams worldwide and develop an AI-powered distributed biopharmaceutical innovation network.
Buying clinical-stage weight-loss drugs has emerged as an unexpected crypto payments use case, according to a July 20 Bloomberg report cited by Foresight News. The report says the market, much of it tied to peptides sold as research chemicals, is running at a pace that would top $100 million a year. Many of the buyers are not crypto natives but ordinary consumers who learned how to buy and send Bitcoin only because sellers would not accept cards or bank transfers. Bloomberg described one such buyer, Zach, a 49-year-old marketing director in the U.S. Pacific Northwest, who opened a Coinbase account and bought Bitcoin for the first time to purchase 20 vials of retatrutide from a Chinese seller for $240. He had previously viewed Bitcoin as a speculative asset with no intrinsic value, but the price gap versus U.S. resellers made the transaction worth the risk in his view. Chainalysis said gray-market peptide sellers took in $32 million in crypto in the first quarter of 2026, up 700% year over year, while TRM Labs estimated $41.4 million of crypto inflows in 2025, up 20%. The report also notes that if U.S. regulators move to legalize domestic production of some peptides, the role crypto fills in this market could shrink.
Bio Protocol officially launched the PEPTAI token on Base Chain, integrating an AI agent for peptide drug discovery. 20% of supply is allocated to BIO stakers. The token's market cap briefly exceeded $15 million within 5 minutes, stabilizing at $13.5 million with $2.2 million trading volume.
NobleBlocks introduces a blockchain-based decentralized science (DeSci) platform, tackling inefficiency, bias, and high costs in traditional publishing through immutable records, peer-to-peer review, and tokenized incentives.
Nexa, developed by Bitcoin Unlimited, advances the UTXO model for enterprise use cases like RWA tokenization, payments, and digital licensing. A 2025 global events strategy positions it as a scalable blockchain for real-world industries.
Boston Blockchain Week 2025 will run from Sept. 9 to 13 across Greater Boston, bringing together 500+ participants, 100+ speakers, and a $44,000 startup pitch competition centered on blockchain, AI, and digital infrastructure.
